Nasdaq
$0.4152▲ 2.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $13.9MShares out 33.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.16After-hours26.09.17 05:068-KKey event#●●●
Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp.'s warrants to purchase common stock (KTTAW) will expire on September 17, 2026, and will be delisted from the Nasdaq Capital Market. Any warrants not exercised prior to this expiration date will cease to be exercisable and lose all value.…more
$0.4152+2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.16After-hours26.09.17 05:0425-NSEOther
Pasithea Therapeutics Corp.
The Nasdaq Stock Market has officially delisted Pasithea Therapeutics (KTTA), with the removal from listing and registration effective as of September 16, 2026. Consequently, the company's securities are no longer traded on the exchange.…more
$0.4152+2.47%vs prev closeView filingShare - 9.9After-hours26.09.10 05:208-KKey event
Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. received shareholder approval for a reverse stock split at its annual meeting on September 9, 2026. The Board of Directors is authorized to effect a reverse split at a ratio between 1:2 and 1:20 at any time within one year. Additionally, the company confirmed the election of two directors and the appointment of its independent accounting firm.…more
$0.4152+2.47%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 22:15#●●●#●●●
Pasithea Announces Positive Phase 1 Clinical Data for PAS-004 Cancer Treatment…more
Pasithea reported positive Phase 1 clinical data for its MEK inhibitor PAS-004, demonstrating favorable long-term tolerability and stable disease in advanced cancer patients. The study showed no dose-limiting toxicities, supporting the potential for chronic, once-daily dosing.…more
$0.4152+2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.14Pre-market26.09.14 20:08
●●●●●●●● ●●●●● ●●●●●●
Pasithea Therapeutics announced it will present initial Phase 1/1b clinical data for its neurofibromatosis treatment, PAS-004, at the European Neurofibromatosis Conference in November. This event marks the company's first public disclosure of clinical results from the trial's Part A.…more
$0.4152+2.47%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 20:00
●●●●●●●● ●●●●● ●●●●●●
Pasithea Therapeutics announced it will present initial clinical data from its Phase 1/1b trial of PAS-004 in adult NF1 patients at the upcoming European Neurofibromatosis Conference. This marks the company's first public disclosure of data from this trial, providing an update on its lead drug candidate.…more
$0.4152+2.47%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report